Psilocybin: Hype or Signal?

A single 25 mg dose of psilocybin. One supervised session. And then — for the next six weeks — a clinically substantial reduction in depression scores, with no pill to refill and no daily adherence to manage. That's the claim from a Phase 2 RCT published in JAMA, and the numbers are hard to dismiss. The question isn't whether the signal is real. The question is whether you can trust it. This video breaks down the trial design, the primary outcome data, the safety profile, and the methodological problems that keep this from landing as a practice-changer. Centralized blinded raters, an active niacin comparator, and a 6-week follow-up make this the best-designed psilocybin trial to date. Sponsor-controlled data management, near-certain blinding failure, a 9-to-1 dropout differential, and a sustained remission rate that didn't reach significance in the primary analysis are the reasons the Castelli Coefficient lands at 7 — not higher.📊 KEY FINDINGS• MADRS reduction from baseline to day 43: −19.1 pts (psilocybin) vs −6.8 pts (niacin) — between-group difference −12.3 pts (95% CI −17.5 to −7.2)• Effect appeared by day 8 (−12.0 pt difference) and held flat through day 43 — no attenuation across any timepoint• Sustained response (≥50% reduction at all 4 post-dose visits): 42% psilocybin vs 11% niacin (OR 5.6; 95% CI 1.9–16.7)• Sheehan Disability Scale at day 43: −2.31 mean difference (95% CI −3.50 to −1.11) — real-world functional improvement in work, social, and home domains• Sustained remission (MADRS ≤10 at all 4 visits): 25% vs 9% — did not reach statistical significance in the primary ITT analysis (p = .05)• Severe adverse events: 8% psilocybin vs 0% niacin; no serious treatment-emergent adverse events; no suicidal behavior in either arm🔗 LINKS & RESOURCESFull paper: Raison CL, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330(9):843–853. DOI: 10.1001/jama.2023.14530⚕️ ABOUT DISPENSE AS WRITTENEvidence-based medicine without the fluff. Every video ends with the Castelli Coefficient — a verdict that incorporates study design, statistical validity, and clinical applicability. No pharmaceutical sponsorships. No conflicts of interest. Just the data. Gregory Castelli, PharmD, FCCP, BCPS, BC-ADM, CDCESAssociate ProfessorDispense As Written, LLC 📱 FIND USYouTube: @dispenseaswrittenInstagram / TikTok: @gregcastellipharmdX / Twitter: @gregcastellirxEmail: [email protected]⚠️ LEGAL DISCLAIMERThe content provided in this video is for educational and informational purposes only. It is intended for healthcare professionals and medical students as a supplement to — not a substitute for — clinical judgment, professional training, and the individualized care of patients. Nothing in this video constitutes medical advice, and it should not be used as the basis for any clinical decision regarding an individual patient. Always consult current clinical guidelines, institutional protocols, and your own clinical judgment when making treatment decisions. Gregory Castelli, PharmD, is speaking in his personal capacity as an educator. The views expressed do not represent the official positions of any affiliated institution. This channel has no affiliation with, and has received no funding or compensation from, any pharmaceutical manufacturer, device company, insurance company, or other commercial entity with a financial interest in the content discussed. Use of trade names is for identification purposes only and does not constitute endorsement. Produced by Dispense As Written, LLC.